Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Infliximab in Polymyositis/Dermatomyositis/Inclusion Body Myositis

Principal Investigator:

Ingrid Lundberg, Karolinska Institute

Study Design:

Phase 2 Open trial, Infliximab dose 5 mg/kg

Types & Number of IIM Studied:

Active Polymyositis/Dermatomyositis/Inclusion Body Myositis with reduced muscle function (N = 15)

Entry Criteria:

Refractory to prednisolone and methotrexate

IMACS Core Set Measures Included:

Physician and Patient Global Activity and Damage Assessments, Health Assessment Questionnaire, Manual Muscle Testing, muscle enzymes, Myositis Disease Activity Assessment Tool; Myositis Damage Index, Health-Related Quality of Life by SF-36

Other Measures Included:

Myositis Functional Index, aerobic capacity, biopsies

Primary Outcome:

Improved functional index and decreased inflammation in muscle biopsies

Study Duration:

16 weeks


Schering Plough


Started in 2003. Enrollment completed.


Dastmalchi M1, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg I. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies., Ann Rheum Dis, 2008 Dec;67(12):1670-7. [Abstract]


Ingrid Lundberg, M.D., Ph.D.
Rheumatology Unit
Department of Medicine
Karolinska University Hospital
Solna, Karolinska Institutet
SE- 171 76 Stockholm, Sweden
Tel 011-46-8-5177-3080

Return to Studies in the Repository listing

to Top